Continuous sunitinib treatment in patients with advanced hepatocellular carcinoma: A swiss group for clinical cancer research (SAKK) and swiss association for the study of the liver (SASL) multicenter phase II trial (SAKK 77/06)

Oncologist

Volumn 15, Issue 3, 2010, Pages 285-292

  Koeberle, Dieter ^a   Montemurro, Michael ^b   Samaras, Panagiotis ^c   Majno, Pietro ^d,e   Simcock, Mathew ^f   Limacher, Andreas ^f   Lerch, Stefanie ^f   Katalin, Kovàcs ^g   Inauen, Roman ^a   Hess, Vivianne ^h   Saletti, Piercarlo ⁱ   Borner, Markus ^j   Roth, Arnaud ^d   Bodoky, György ^g  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d UNIVERSITY HOSPITAL   (Switzerland)

^e SASL   (Switzerland)

^f SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

^g St László Teaching Hospital   (Hungary)

^h UNIVERSITY HOSPITAL BASEL   (Switzerland)

ⁱ ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^j UNIVERSITY OF BERN   (Switzerland)

more..

Author keywords

Hepatocellular carcinoma; RECIST; Sunitinib; Tyrosine kinase inhibitor

Indexed keywords

SUNITINIB; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER RESEARCH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DISEASE ACTIVITY; DISEASE DURATION; DISTANT METASTASIS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVENING DOSAGE; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPOTHYROIDISM; LIVER CELL CARCINOMA; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QT PROLONGATION; SIDE EFFECT; SURVIVAL TIME; SWITZERLAND; TASTE DISORDER; THROMBOCYTOPENIA; CARCINOMA, HEPATOCELLULAR; DISEASE FREE SURVIVAL; LIVER NEOPLASMS; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INDOLES; LIVER NEOPLASMS; MALE; MIDDLE AGED; PYRROLES; TREATMENT OUTCOME;

EID: 77950546450     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2009-0316     Document Type: Article

References (30)

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001; 2:533-543.
2. McGlynn KA, Tsao L, Hsing AW et al. International trends and patterns of primary liver cancer. Int J Cancer 2001;94:290-296.
3. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745-750.
4. Llovet JM, Fuster J, Bruix J. The Barcelona approach: Diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transplant 2004;10: S115-S120.
5. Abou-Alfa GK. Current and Novel Therapeutics for Hepatocellular Carcinoma. In: American Society of Clinical Oncology Educational Book. Alexandria, VA: American Society of Clinical Oncology, 2004:192-197.
6. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390.
7. Llovet JM, Di Bisceglie AM, Bruix J et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008;100:698-711.
8. Faivre S, Delbaldo C, Vera K et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006;24:25-35.
9. Chow LQ, Eckhardt SG. Sunitinib: From rational design to clinical efficacy. J Clin Oncol 2007;25:884-896.
10. Zhu AX, Sahani DV, Duda DG et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: A phase II study. J Clin Oncol 2009;27:3027-3035.
11. Faivre S, Raymond E, Boucher E et al. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: An open-label, multicen-tre, phase II study. Lancet Oncol 2009;10:794-800.
12. Kisker O, Becker CM, Prox D et al. Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res. 2001; 61:7669-7674.
13. Ebos JM, Lee CR, Cruz-Munoz W et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009;15:232-239.
14. Escudier B, Roigas J, Gillessen S et al. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol 2009;27:4068-4075.
15. George S, Blay JY, Casali PG et al. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer 2009;45:1959-1968.
16. Bruix J, Sherman M, Llovet JM et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference Eu- ropean Association for the Study of the Liver. J Hepatol 2001;35:421-430.
17. Pugh RN, Murray-Lyon IM, Dawson JL et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-649.
18. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Re-search and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92: 205-216.
19. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1-10.
20. Choi H, Charnsangavej C, Faria SC et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastro-intestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria. J Clin Oncol 2007;25:1753-1759.
21. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008;48:1312-1327.
22. Höpfner M, Schuppan D, Scherbl H. Growths factor receptors and related signaling pathways as targets for novel treatment strategies of hepatocellular cancer. World J Gastroenterol 2008;14:1-14.
23. Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
24. Sahin F, Kannangai R, Adegbola O et al. mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res 2004;10:8421-8425.
25. Siegel AB, Cohen EI, Ocean A et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 2008;26:2992-2998.
26. Abou-Alfa GK, Schwartz L, Ricci S et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24: 4293-4300.
27. Vora SR, Zheng H, Stadler ZK et al. Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma. The Oncologist 2009;14:717-725.
28. Chan SL, Mo FK, Johnson PJ et al. New utility of an old marker: Serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. J Clin Oncol 2009;27:446-452.
29. Gillessen S, Graf L, Korte W et al. Macrocytosis and cobalamin deficiency in patients treated with sunitinib. N Engl J Med 2007;356:2330-2331.
30. 12) levels in blood. Clin Biochem 2003;36:585-590.